Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rani Therapeutics Holdings, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-08-02 | Direct | 247,200 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 247,200 · Balance 247,200 F1: The shares subject to the option will vest and become exercisable over a three-year period, with 1/3rd of shares vesting on the first anniversary of the grant date and 1/36th of the shares vesting in equal monthly installments thereafter, such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date, and will vest in full upon a Change in Control (as defined in the 2021 Plan), subject to the Reporting Person's Continuous Service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable over a three-year period, with 1/3rd of shares vesting on the first anniversary of the grant date and 1/36th of the shares vesting in equal monthly installments thereafter, such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date, and will vest in full upon a Change in Control (as defined in the 2021 Plan), subject to the Reporting Person's Continuous Service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arcellx, Inc.
Report date April 28, 2026 · Filed April 28, 2026
Section 16 reporting ended · disclosed 2026-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 1
1 source rowRow 1 · 2026-04-28 · Other · Disposed 67,048 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | IndirectBy foundation | 0 |
Reported balance
After 2026-04-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-04-28 · Other · Disposed 5,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. F2: Shares held by a a family charitable foundation, of which the Reporting Person serves as the President. The Reporting Person has voting and investment power over all securities owned by the foundation. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.66 · Expires 2032-05-23 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-28 · Disposition to issuer · Disposed 40,205 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.97 · Expires 2032-09-28 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-28 · Disposition to issuer · Disposed 32,500 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.03 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-28 · Disposition to issuer · Disposed 70,796 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.15 · Expires 2034-01-02 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-28 · Disposition to issuer · Disposed 94,596 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-28 · Disposition to issuer · Disposed 20,496 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F5: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-28 · Disposition to issuer · Disposed 61,590 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F5: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-28 · Disposition to issuer · Disposed 88,542 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F5: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
| Performance-based Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 59,028 |
Reported balance
After 2026-04-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-28 · Grant · Acquired 59,028 · Balance 59,028 F4: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F5: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
| Performance-based Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-28 · Disposition to issuer · Disposed 59,028 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F5: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: Shares held by a a family charitable foundation, of which the Reporting Person serves as the President. The Reporting Person has voting and investment power over all securities owned by the foundation.
F3: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
F4: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
F5: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2025 Filed Jan 7, 2025 02:54 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 5,502 | $79.55 | $437,673.65 |
DisclosureSEC source: 0001415889-25-000952 · form4-01072025_020104.xml · nonDerivative · entry 3 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,332 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices that were not available from the broker at the time of filing. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 02:54 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 15,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000952 · form4-01072025_020104.xml · nonDerivative · entry 2 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 03, 2025 Filed Jan 11, 2025 02:36 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionRestricted Stock Unit · Derivative | 15,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001345 · form4-01112025_020131.xml · derivative · entry 8 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,340 Underlying: Common Stock · 15,339 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Vesting of these RSUs previously reported in the Form 4 filed January 6, 2025. F9 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023. F9 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023. Read SEC document |
| January 03, 2025 Filed Jan 11, 2025 02:36 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 15,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001345 · form4-01112025_020131.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Vesting of these RSUs previously reported in the Form 4 filed January 6, 2025. Read SEC document |
| January 03, 2025 Filed Jan 11, 2025 02:28 UTC Amendment | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 5,622 | $79.55 | $447,219.42 |
DisclosureSEC source: 0001415889-25-001341 · form4a-01112025_020153.xml · nonDerivative · entry 2 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,212 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F3 · shares: Amendment filed to report the correct number of shares sold to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units reported in the Form 4 filed on January 6, 2025. F4 · price: The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices that were not available from the broker at the time of filing. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 02:54 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionRestricted Stock Unit · Derivative | 20,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000952 · form4-01072025_020104.xml · derivative · entry 5 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,992 Underlying: Common Stock · 20,495 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 2, 2024. F4 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 2, 2024. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 02:54 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 20,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000952 · form4-01072025_020104.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 02, 2025 Filed Jan 11, 2025 02:28 UTC Amendment | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionRestricted Stock Units · Derivative | 20,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001341 · form4a-01112025_020153.xml · derivative · entry 4 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,992 Underlying: Common Stock · 20,495 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Vesting of these RSUs previously reported in the Form 4 filed January 6, 2025. F5 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 2, 2024. F5 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 2, 2024. Read SEC document |
| January 02, 2025 Filed Jan 11, 2025 02:28 UTC Amendment | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 20,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001341 · form4a-01112025_020153.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Vesting of these RSUs previously reported in the Form 4 filed January 6, 2025. Read SEC document |
| November 19, 2024 Filed Nov 19, 2024 23:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $8.66 | $0.00 |
DisclosureSEC source: 0001415889-24-027269 · form4-11192024_111127.xml · derivative · entry 6 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,315 Underlying: Common Stock · 3,000 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 23, 2022. Read SEC document |
| November 19, 2024 Filed Nov 19, 2024 23:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 3,000 | $8.66 | $25,980.00 |
DisclosureSEC source: 0001415889-24-027269 · form4-11192024_111127.xml · nonDerivative · entry 5 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 23:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 100 | $95.00 | $9,500.00 |
DisclosureSEC source: 0001415889-24-027269 · form4-11192024_111127.xml · nonDerivative · entry 4 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 23:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 100 | $91.67 | $9,167.00 |
DisclosureSEC source: 0001415889-24-027269 · form4-11192024_111127.xml · nonDerivative · entry 3 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 23:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 500 | $89.17 | $44,586.00 |
DisclosureSEC source: 0001415889-24-027269 · form4-11192024_111127.xml · nonDerivative · entry 2 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 500 shares sold in the price range of $88.74 to $89.66 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 23:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,061 | $87.89 | $93,255.43 |
DisclosureSEC source: 0001415889-24-027269 · form4-11192024_111127.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 700 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 1,061 shares sold in the price range of $87.36 to $88.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 7,200 | $0.00 Strike: $8.66 | $0.00 |
DisclosureSEC source: 0001415889-24-026655 · form4-11132024_011117.xml · derivative · entry 5 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,315 Underlying: Common Stock · 7,200 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), "Vesting Commencement Date" shall mean May 23, 2022. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 801 | $102.33 | $81,970.17 |
DisclosureSEC source: 0001415889-24-026655 · form4-11132024_011117.xml · nonDerivative · entry 4 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,761 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. F4 · price: Represents the weighted average share price of an aggregate total of 801 shares sold in the price range of $102.055 to $102.56 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,853 | $101.27 | $187,646.27 |
DisclosureSEC source: 0001415889-24-026655 · form4-11132024_011117.xml · nonDerivative · entry 3 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,562 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 1,853 shares sold in the price range of $101.03 to $101.99 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 9,700 | $100.26 | $972,554.01 |
DisclosureSEC source: 0001415889-24-026655 · form4-11132024_011117.xml · nonDerivative · entry 2 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,415 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 9,700 shares sold in the price range of $99.99 to $100.98 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 01:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 7,200 | $8.66 | $62,352.00 |
DisclosureSEC source: 0001415889-24-026655 · form4-11132024_011117.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 00:54 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.66 | $0.00 |
DisclosureSEC source: 0001415889-24-023587 · form4-09182024_120949.xml · derivative · entry 4 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,515 Underlying: Common Stock · 15,000 shares Expires 2032-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), "Vesting Commencement Date" shall mean May 23, 2022. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 00:54 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 8,726 | $77.88 | $679,588.73 |
DisclosureSEC source: 0001415889-24-023587 · form4-09182024_120949.xml · nonDerivative · entry 3 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,915 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 8,726 shares sold in the price range of $77.70 to $78.30 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 00:54 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 6,274 | $77.51 | $486,290.84 |
DisclosureSEC source: 0001415889-24-023587 · form4-09182024_120949.xml · nonDerivative · entry 2 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,641 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 6,274 shares sold in the price range of $76.70 to $77.69 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 00:54 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 15,000 | $8.66 | $129,900.00 |
DisclosureSEC source: 0001415889-24-023587 · form4-09182024_120949.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:06 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 551 | $54.25 | $29,891.20 |
DisclosureSEC source: 0001415889-24-018407 · form4-06282024_080637.xml · nonDerivative · entry 2 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,915 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 551 shares sold in the price range of $54.18 to $54.44 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:06 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 12,326 | $53.68 | $661,627.63 |
DisclosureSEC source: 0001415889-24-018407 · form4-06282024_080637.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,466 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023 and subsequently modified March 27, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 12,326 shares sold in the price range of $53.18 to $54.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 24, 2024 Filed May 25, 2024 00:16 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 12,121 | $50.71 | $614,655.91 |
DisclosureSEC source: 0001415889-24-014599 · form4-05252024_120534.xml · nonDerivative · entry 2 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,792 F2 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| May 23, 2024 Filed May 25, 2024 00:16 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionRestricted Stock Units · Derivative | 22,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014599 · form4-05252024_120534.xml · derivative · entry 3 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,429 Underlying: Common Stock · 22,428 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, the RSUs shall vest annually over three (3) years with a cliff every twelve (12) months on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 23, 2022. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, the RSUs shall vest annually over three (3) years with a cliff every twelve (12) months on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 23, 2022. Read SEC document |
| May 23, 2024 Filed May 25, 2024 00:16 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 22,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014599 · form4-05252024_120534.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 00:49 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 3,043 | $69.73 | $212,192.35 |
DisclosureSEC source: 0001415889-24-008370 · form4-03192024_120347.xml · nonDerivative · entry 2 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,485 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023. F3 · price: Represents the weighted average share price of an aggregate total of 3,043 shares sold in the price range of $69.50 to $70.4999 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 00:49 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 3,782 | $69.03 | $261,063.14 |
DisclosureSEC source: 0001415889-24-008370 · form4-03192024_120347.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,528 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 18, 2023. F2 · price: Represents the weighted average share price of an aggregate total of 3,782 shares sold in the price range of $68.44 to $69.4399 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:04 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 8,514 | $55.27 | $470,550.90 |
DisclosureSEC source: 0001209191-24-001121 · doc4.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,310 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices that were not available from the broker at the time of filing. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 00:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionRestricted Stock Unit · Derivative | 15,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000918 · doc4.xml · derivative · entry 4 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,679 Underlying: Common Stock · 15,339 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023. F4 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 00:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantRestricted Stock Unit · Derivative | 61,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000918 · doc4.xml · derivative · entry 3 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,487 Underlying: Common Stock · 61,487 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 2, 2024. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 2, 2024. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 00:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 94,596 | $0.00 Strike: $56.15 | $0.00 |
DisclosureSEC source: 0001209191-24-000918 · doc4.xml · derivative · entry 2 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,596 Underlying: Common Stock · 94,596 shares Expires 2034-01-02 F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Vesting Commencement Date" shall mean January 1, 2024. Read SEC document |
| May 25, 2023 Filed May 26, 2023 00:21 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 6,000 | $42.77 | $256,616.40 |
DisclosureSEC source: 0001209191-23-032332 · doc4.xml · nonDerivative · entry 4 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,485 F4 · price: Represents the weighted average share price of an aggregate total of 6,000 shares sold in the price range of $42.73 to $42.8605 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:21 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 150 | $41.64 | $6,246.00 |
DisclosureSEC source: 0001209191-23-032332 · doc4.xml · nonDerivative · entry 3 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,485 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:21 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 8,554 | $42.47 | $363,288.38 |
DisclosureSEC source: 0001209191-23-032332 · doc4.xml · nonDerivative · entry 2 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,635 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| May 23, 2023 Filed May 26, 2023 00:21 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionRestricted Stock Units · Derivative | 22,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032332 · doc4.xml · derivative · entry 5 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,857 Underlying: Common Stock · 22,428 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, the RSUs shall vest annually over three (3) years with a cliff every twelve (12) months on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 23, 2022. F5 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, the RSUs shall vest annually over three (3) years with a cliff every twelve (12) months on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 23, 2022. Read SEC document |
| May 23, 2023 Filed May 26, 2023 00:21 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 22,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032332 · doc4.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 1,761 shares of Common Stock acquired under the Issuer's 2022 Employee Stock Purchase Plan on May 12, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:45 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantRestricted Stock Unit · Derivative | 46,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001899 · doc4.xml · derivative · entry 2 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,018 Underlying: Common Stock · 46,018 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:45 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 70,796 | $0.00 Strike: $31.03 | $0.00 |
DisclosureSEC source: 0001209191-23-001899 · doc4.xml · derivative · entry 1 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,796 Underlying: Common Stock · 70,796 shares Expires 2033-01-03 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Vesting Commencement Date" shall mean January 1, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2024 00:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 15,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000918 · doc4.xml · nonDerivative · entry 1 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:14 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $19.97 | $0.00 |
DisclosureSEC source: 0001209191-22-051631 · doc4.xml · derivative · entry 1 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2032-09-28 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Vesting Start Date on the same day of the month as the Vesting Start Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Vesting Start Date" shall mean January 1, 2023. Read SEC document |
| May 23, 2022 Filed May 24, 2022 22:56 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantRestricted Stock Units · Derivative | 67,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031729 · doc4.xml · derivative · entry 2 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,285 Underlying: Common Stock · 67,285 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACLX common stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, the restricted stock units shall vest annually over three (3) years with a cliff every twelve (12) months on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 23, 2022. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, the restricted stock units shall vest annually over three (3) years with a cliff every twelve (12) months on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 23, 2022. Read SEC document |
| May 23, 2022 Filed May 24, 2022 22:56 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 103,515 | $0.00 Strike: $8.66 | $0.00 |
DisclosureSEC source: 0001209191-22-031729 · doc4.xml · derivative · entry 1 Gilson Michelle · CIK 0001930862 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,515 Underlying: Common Stock · 103,515 shares Expires 2032-05-23 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), "Vesting Commencement Date" shall mean May 23, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.